Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer

Breast Cancer Research

Volumn 16, Issue 3, 2014, Pages

  Chung, Liping ^a   Moore, Katrina ^b   Phillips, Leo ^a   Boyle, Frances M ^c   Marsh, Deborah J ^a   Baxter, Robert C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Mater Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; BETA2 GLYCOPROTEIN 1; COMPLEMENT COMPONENT C3A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PREALBUMIN; PROGESTERONE RECEPTOR; BIOLOGICAL MARKER; PLASMA PROTEIN; TUMOR MARKER;

ADULT; ANION EXCHANGE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SIZE; CATION EXCHANGE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING; BLOOD ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR VOLUME; BLOOD; BREAST NEOPLASMS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MORTALITY;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-I; BETA 2-GLYCOPROTEIN I; BLOOD PROTEINS; BREAST NEOPLASMS; COMPLEMENT C3A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PREALBUMIN; RECEPTORS, ESTROGEN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84903526334     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3676     Document Type: Article

References (36)

1. Chung L, Baxter RC. Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Rev Proteomics 2012, 9:599-614.
2. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
3. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem 2006, 52:345-351.
4. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
5. Hathout Y, Gehrmann ML, Chertov A, Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett 2004, 210:245-253.
6. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003, 278:6482-6489.
7. Leong S, McKay MJ, Christopherson RI, Baxter RC. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL. J Proteome Res 2012, 11:1240-1250.
8. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005, 12:185-213.
9. Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG, King BL. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res 2005, 7:R1017-1022.
10. Chung L, Shibli S, Moore K, Elder EE, Boyle FM, Marsh DJ, Baxter RC. Tissue biomarkers of breast cancer and their association with conventional pathologic features. Br J Cancer 2013, 108:351-360.
11. Dwek MV, Alaiya AA. Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br J Cancer 2003, 89:305-307.
12. Hwang SI, Thumar J, Lundgren DH, Rezaul K, Mayya V, Wu L, Eng J, Wright ME, Han DK. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 2007, 26:65-76.
13. Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL, Caprioli RM. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 2008, 7:1500-1507.
14. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
15. Chung L, Clifford D, Buckley M, Baxter RC. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab 2006, 91:671-677.
16. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 2002, 99:6562-6566.
17. Chung L, Nelson AE, Ho KK, Baxter RC. Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes. J Clin Endocrinol Metab 2009, 94:3038-3043.
18. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
19. Opstal-van Winden AW, Krop EJ, Karedal MH, Gast MC, Lindh CH, Jeppsson MC, Jonsson BA, Grobbee DE, Peeters PH, Beijnen JH, van Gils CH, Vermeulen RC. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011, 11:381.
20. Gonçalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng XY, Fung ET, Birnbaum D, Maraninchi D, Viens P, Borg JP. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25:981-989.
21. Fan Y, Wang J, Yang Y, Liu Q, Yu J, Zheng S, Li M. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol 2010, 136:1243-1254.
22. Poste G. Bring on the biomarkers. Nature 2011, 469:156-157.
23. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG) Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009, 117:319-324. International Breast Cancer Study Group (IBCSG).
24. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001, 180:35-48.
25. Solassol J, Rouanet P, Lamy PJ, Allal C, Favre G, Maudelonde T, Mange A. Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene 2010, 29:550-560.
26. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 2006, 96:83-90.
27. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, Roman JM, Oevermann E, Schiedeck T, Homann N, Duchrow M, Conrads TP, Veenstra TD, Burt SK, Bruch HP, Auer G, Ried T. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131:1020-1029. quiz 1284.
28. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94:1898-1905.
29. Rompp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM. Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics 2007, 7:474-481.
30. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
31. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
32. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005, 5:4581-4588.
33. Brauer HA, Lampe PD, Yasui YY, Hamajima N, Stolowitz ML. Biochips that sequentially capture and focus antigens for immunoaffinity MALDI-TOF MS: a new tool for biomarker verification. Proteomics 2010, 10:3922-3927.
34. Meng Z, Veenstra TD. Targeted mass spectrometry approaches for protein biomarker verification. J Proteomics 2011, 74:2650-2659.
35. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010, 107:19997-20002.
36. Pettingale KW, Tee DE. Serum protein changes in breast cancer: a prospective study. J Clin Pathol 1977, 30:1048-1052.